Search

Your search keyword '"Nava-Rodrigues, Daniel"' showing total 195 results

Search Constraints

Start Over You searched for: Author "Nava-Rodrigues, Daniel" Remove constraint Author: "Nava-Rodrigues, Daniel"
195 results on '"Nava-Rodrigues, Daniel"'

Search Results

1. Development and Validation of a New BAG-1L–Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer

2. Supplementary Figure 7 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

3. Supplementary Figure 12 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

4. Data from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

5. Supplementary Figure 3 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

6. Supplementary Figure 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

7. Supplementary Table 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

8. Supplementary Figure 9 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

9. Supplementary Table 6 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

10. Supplementary Table 1 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

11. Supplementary Table 3 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

12. Supplementary Figure 8 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

13. Supplementary Materials and Methods from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

14. Supplementary Figure 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

15. Supplementary Figure 6 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

16. Supplementary Table 7 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

17. Supplementary Table 4 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

18. Supplementary Table 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

19. Supplementary Figure 4 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

20. The impact of rattlesnake venom on mice cerebellum proteomics points to synaptic inhibition and tissue damage

21. Supplementary Figure S5 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

22. Supplementary Video S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

23. Supplementary Tables S1-S19 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

24. Supplementary Methods S1 from Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

25. BCL2 expression is enriched in androgen receptor-negative advanced prostate cancer

26. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer

27. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

28. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

29. Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer.

30. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer

31. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

32. Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses

33. Supplementary Data 2 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

34. Supplementary Data 4 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

35. Data from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

36. Figure S1 from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer

37. Supplementary Data 3 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

38. Supplementary Legends from RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer

39. supplementary Data 1-7 from Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

40. Supplementary Methods from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

41. Supplementary Data from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

42. Figure Legends from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

43. Supplementary Data 6 from Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration

44. Supplementary Figures from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

45. Supplementary Data 1 from Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

46. Supplementary Tables from Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)

48. Systematic study of tissue factor expression in solid tumors

49. Systematic study of tissue factor expression in solid tumors.

Catalog

Books, media, physical & digital resources